Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Sanofi MS drug nears green light after pass-the-parcel marathon
Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Treatment of acute transverse myelitis and its early complications.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.

Pages